News

Neurology News Network for the week ending February 26, 2022. [WATCH TIME: 3 minutes]

An analysis of patients with MOGAD showed that only 50% of those treated with various immunotherapies over a long-term period maintained relapse-free status.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 24, 2023.

Between pretreatment naïve patients and those previously on disease-modifying therapies, treatment with cladribine resulted in stable scores on Symbols Digit Modalities Test and other cognitive assessments.

The multiple sclerosis fellow at Michigan Institute for Neurologic Disorders provided perspective on the clinical utility and advantages of a multi-protein test that assesses multiple sclerosis disease activity. [WATCH TIME: 3 minutes]

Secondary findings from a phase 3 study demonstrate a significant decrease in new T1 enhancing lesions and new enlarging hyperintense T2 lesions in patients with multiple sclerosis undergoing glatiramer acetate depot treatment.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Darin Okuda, MD. [LISTEN TIME: 21 minutes]

Study results suggest that selected interventions should be based on phenotypic differences and treatment goals.

Non-Hispanic Black and Hispanic or Latino individuals on ocrelizumab did not demonstrate significantly greater risk on 24-week confirmed disability progression relative to non-Hispanic Whites.

The program committee vice-chair of ACTRIMS discussed the continued efforts to understand inflammation and neurodegeneration of multiple sclerosis. [WATCH TIME: 3 minutes]

To honor Black History Month, NeurologyLive® spoke with influential Black clinicians on the leaders they look up to, the ongoing fight to overcome racial disparities, and ways to encourage diversity in health care.

The neurologist at Mayo Clinic in Jacksonville Florida talked about the significance of the ExTINGUISH trial, regarding care for patients with autoimmune encephalitis. [WATCH TIME: 4 minutes]

Stanley Appel, MD, shared his insight into the MDA session track on amyotrophic lateral sclerosis, the latest science advances to benefit patients, and where the field is headed with research and treatment.

Gregory Day, MD, MSc, MSCI, FAAN, a neurologist at Mayo Clinic in Jacksonville Florida, talked about the current state of treating autoimmune encephalitis and the significance of the ExTINGUISH trial.

In honor of World Encephalitis Day, held February 22, 2023, get caught up on some of the latest news in autoimmune encephalitis as the NeurologyLive® team shares some of our data updates and expert insights.

The associate professor at Harvard Medical School spoke with NeurologyLive® about the differences between patients with multiple sclerosis and those with NMOSD. [WATCH TIME: 3 minutes]

Epworth Sleepiness Scale scores improved by an average of 4.3 points overall, with more than 90% of patients reporting perceived improvements in their excessive daytime sleepiness.

The program committee vice-chair of ACTRIMS provided perspective on the upcoming forum, including the notable sessions, themes, and presentations the clinical community should be aware of. [WATCH TIME: 7 minutes]

The director of Cleveland Clinic’s Cerebrovascular Center provided clinical perspective on the treatment decisions mobile stroke units face, and whether directly transferring patients to angiography suite is necessary.

Researchers designed a new screening tool to assist nonmovement disorders specialists with identifying involuntary movements in patients aged at least 4 years of age with an inborn error of metabolism.

To honor Black History Month, NeurologyLive® spoke with influential Black clinicians on the leaders they look up to, the ongoing fight to overcome racial disparities, and ways to encourage diversity in health care.

The senior vice president and chief scientific officer of the Parkinson’s Foundation provided perspective on recently published findings showing a nearly doubling of Parkinson disease incidence that previously reported. [WATCH TIME: 4 minutes]

Patients who switched from a previous disease-modifying therapy to teriflunomide saw a decrease in annualized relapse rate and stability with Expanded Disability Status Scale scores regardless of subgroups.

To honor Black History Month, NeurologyLive® spoke with influential Black clinicians on the leaders they look up to, the ongoing fight to overcome racial disparities, and ways to encourage diversity in health care.

In honor of American Heart Month, held February 2023, get caught up on some of the latest news in stroke as the NeurologyLive® team shares some of our data updates.

Daniel Ontaneda, MD, program committee vice-chair of ACTRIMS, provided insight on the notable sessions and themes clinicians should pay attention to at this year’s forum, which takes place February 23-25, in San Diego, California.

Brian Grosberg, MD, and Stephanie Bakaysa, MD, of Hartford HealthCare Medical Group, offered their clinical perspectives on the recently published survey study on management for migraines during pregnancy.

Here's some of what is coming soon to NeurologyLive® this week.